Ramani – Pulmonary Hypertension for the Pulmonologist | Maryland CC Project

The podcast addresses the updated definition, classification, and management of pulmonary hypertension (PH). It highlights the redefinition of pulmonary hypertension as a mean PA pressure greater than 20 mmHg and emphasizes the importance of pulmonary vascular resistance (PVR) in distinguishing between different types of PH. The discussion covers the classification of PH into five groups, stressing the therapeutic implications of accurate categorization, as giving pulmonary vasodilators indiscriminately can be harmful. The podcast further explores the role of echocardiography in screening for PH, focusing on metrics beyond right ventricular systolic pressure. It also touches on the limited treatment options for HF-PEF and the excitement surrounding inhaled Triprostanil for ILD-associated PH, based on preliminary results from the INCREASE study.

Outlines

Part 1: Definitions, Classification, and Pathophysiology

Part 2: Screening, Metrics, and HF-PEF Research

Part 3: Group 3 PH and Lung Disease Studies

Part 4: Risk Assessment, Technology, and Future Directions

Sign in to continue reading, translating and more.

Continue

Ramani – Pulmonary Hypertension for the Pulmonologist

Maryland CC Project

Part 1: Definitions, Classification, and Pathophysiology

Redefining Pulmonary Hypertension: Updated Definitions and Significance of PVR

PAH Classification, Genetic Testing, and Therapeutic Implications

Pathophysiology, Vasodilator Challenge, and Calcium Channel Blockers in PAH

Part 2: Screening, Metrics, and HF-PEF Research

Echocardiogram Metrics, Prevalence, and Distinguishing Pulmonary Hypertension Types

Phenotyping HF-PEF, Spironolactone Benefits, and the TopCat Study

Sildenafil in HF-PEF, VA Study, and the Serenade Study

Part 3: Group 3 PH and Lung Disease Studies

Group 3 Pulmonary Hypertension: A Case Study and Treatment Challenges

ILD-PH and the INCREASE Study: Promising Results with Inhaled Triprostanil

Part 4: Risk Assessment, Technology, and Future Directions

Risk Assessment, Treatment Paradigms, and Emerging Technologies in PH

Sarcoidosis-Associated Pulmonary Hypertension: Treatment Heterogeneity and Future Directions

Ramani – Pulmonary Hypertension for the Pulmonologist

Maryland CC Project

Part 1: Definitions, Classification, and Pathophysiology

00:00Redefining Pulmonary Hypertension: Updated Definitions and Significance of PVR

Redefining Pulmonary Hypertension: Updated Definitions and Significance of PVR

05:05PAH Classification, Genetic Testing, and Therapeutic Implications

PAH Classification, Genetic Testing, and Therapeutic Implications

09:34Pathophysiology, Vasodilator Challenge, and Calcium Channel Blockers in PAH

Pathophysiology, Vasodilator Challenge, and Calcium Channel Blockers in PAH

Part 2: Screening, Metrics, and HF-PEF Research

14:56Echocardiogram Metrics, Prevalence, and Distinguishing Pulmonary Hypertension Types

Echocardiogram Metrics, Prevalence, and Distinguishing Pulmonary Hypertension Types

21:25Phenotyping HF-PEF, Spironolactone Benefits, and the TopCat Study

Phenotyping HF-PEF, Spironolactone Benefits, and the TopCat Study

26:06Sildenafil in HF-PEF, VA Study, and the Serenade Study

Sildenafil in HF-PEF, VA Study, and the Serenade Study

Part 3: Group 3 PH and Lung Disease Studies

29:56Group 3 Pulmonary Hypertension: A Case Study and Treatment Challenges

Group 3 Pulmonary Hypertension: A Case Study and Treatment Challenges

37:14ILD-PH and the INCREASE Study: Promising Results with Inhaled Triprostanil

ILD-PH and the INCREASE Study: Promising Results with Inhaled Triprostanil

Part 4: Risk Assessment, Technology, and Future Directions

40:26Risk Assessment, Treatment Paradigms, and Emerging Technologies in PH

Risk Assessment, Treatment Paradigms, and Emerging Technologies in PH

45:54Sarcoidosis-Associated Pulmonary Hypertension: Treatment Heterogeneity and Future Directions

Sarcoidosis-Associated Pulmonary Hypertension: Treatment Heterogeneity and Future Directions